From January 1988 to December 1997, among 53 acute promyelocytic leukaemia patients in 1st complete remission (CR) after 5 years from diagnosis, we observed 5 late relapses (9.4%) after 60, 61, 71, 101 and 155 months from diagnosis; 3 of those late relapses (7.7%) occurred among 39 patients previously treated with all-trans-retinoic acid. An involvement of the mastoid occurred in 3/5 patients (60%), compared with 2/32 patients (6.3%) at an early relapse (p < 0.02). As to the treatment of the late relapse, 1 patient received all-trans-retinoic acid alone followed by allogeneic transplantation and 4 patients were treated according to the GIMEMA 0191 protocol. All patients achieved a 2nd CR and are still alive: 4 in the 2nd molecular CR after 6, 33, 34 and 115 months; 1 relapsed after 15 months and is now in the 3rd CR. In conclusion, a late relapse occurred in a sizeable fraction of acute promyelocytic leukaemia patients: the high rate of ear involvement might be explained considering the ear as a ‘disease sanctuary’.

1.
Sucic M, Zadro R, Burazer B, Labar B, Nemet D, Mrsic M, Aurer I, Mrsic S, Hitrec V, Boban D, Markovic-Glamocak M, Batinic D, Uzarevic B, Stavljenic-Rukavina A: Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants. J Hematother Stem Cell Res 2002;11:941–950.
2.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo-Coco F: Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014–1021.
3.
Wang Z, Sun G, Shen Z, Chen S, Chen Z: Differentiation therapy for acute promyelocytic leukemia with all-trans retinoid acid: 10-year experience of its application. Chin Med J (Engl) 1999;112:963–967.
4.
Ferrara F, Selleri C, Mele G, Serio B, Palmieri S, Pocali B, Pane F, Rotoli B: Late relapse of acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy: report of two cases. Ann Hematol 2004;83:484–486.
5.
Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F: Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP-0389 with 7 years of minimal follow-up. Blood 2002;100:3141–3146.
6.
Ko BS, Tang JL, Chen YC, Yao M, Wang CH, Shen MC, Thien HF: Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia – the occurrence of retinoic acid syndrome is a risk factor. Leukemia 1999;13:1406–1408.
7.
Breccia M, Carmosino I, Diverio D, De Santis S, De Propris MS, Romano A, Petti MC, Mandelli F, Lo-Coco F: Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol 2003;120:266–270.
8.
Specchia G, Lo-Coco F, Vignetti M, Avvisati G, Fazi P, Albano F, Di Raimondo F, Martino B, Ferrara F, Selleri C, Liso V, Mandelli F: Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell’Adulto. J Clin Oncol 2001;19:4023–4028.
9.
Leskinen K: Complications of acute otitis media in children. Curr Allergy Asthma Rep 2005;5:308–312.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.